Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article - Biomedical Research (2017) Volume 28, Issue 7

Clinical efficacies of initial combined application of lamivudine and adefovir dipivoxil in treating decompensation stage of hepatitis-B caused cirrhosis

This study aims to investigate the clinical efficacies of initial combined application of Lamivudine (LAM) and Adefovir Dipivoxil (ADE) in treating the Decompensation Stage of Hepatitis B-caused Cirrhosis (DS-HBC). 200 DS-HBC patients treated were selected and randomly divided into the Observation group (OBS) and the Control group (CON): The observation group was administrated the initial combined therapy of LAM and ADE, and the control group was co-administrated LAM after ADE-resistance appeared. Such indexes as HBeAg/HBeAb seroconversion, HBV-DNA outcome, Child- Pugh score, and liver functions between the two groups after 6 and 12-month treatment were then compared. The HBeAg/HBeAb seroconversion in OBS was higher than CON (6 month: 37% vs. 19%, 12 month: 69% vs. 43%), the HBV DNA negative-conversion rate was also higher (6 month: 38% vs. 21%, 12 month: 88% vs. 54%), the Child-Pugh score was significantly lower than CON (6 month: 8.9 ± 0.5 vs. 9.2 ± 0.5; 12 month: 7.5 ± 0.4 vs. 8.7 ± 0.9), and the liver functions were better than CON. The differences in the above results between the two groups were statistically significant (P<0.05). The clinical efficacies of initial combined application of LAM and ADE in treating DS-HBC were better those of second-line combined therapy, so it was worthy of promotion.

Author(s): Yi Liu, Yongping Luo

Abstract Full Text PDF